FreshPatents.com Logo
stats FreshPatents Stats
1 views for this patent on FreshPatents.com
2011: 1 views
Updated: June 23 2014
newTOP 200 Companies filing patents this week


    Free Services  

  • MONITOR KEYWORDS
  • Enter keywords & we'll notify you when a new patent matches your request (weekly update).

  • ORGANIZER
  • Save & organize patents so you can view them later.

  • RSS rss
  • Create custom RSS feeds. Track keywords without receiving email.

  • ARCHIVE
  • View the last few months of your Keyword emails.

  • COMPANY DIRECTORY
  • Patents sorted by company.

Follow us on Twitter
twitter icon@FreshPatents

S1p receptor modulating compounds and use thereof

last patentdownload pdfimage previewnext patent


Title: S1p receptor modulating compounds and use thereof.
Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions. ...


Browse recent Epix Pharmaceuticals, Inc. patents - Lexington, MA, US
Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
USPTO Applicaton #: #20110212940 - Class: 51421018 (USPTO) - 09/01/11 - Class 514 
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) >Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai >Hetero Ring Is Four-membered And Includes At Least One Ring Nitrogen >Having -c(=x)-, Wherein X Is Chalcogen, Bonded Directly To The Four-membered Hetero Ring >Additional Hetero Ring Attached Directly Or Indirectly To The Four-membered Hetero Ring By Nonionic Bonding

view organizer monitor keywords


The Patent Description & Claims data below is from USPTO Patent Application 20110212940, S1p receptor modulating compounds and use thereof.

last patentpdficondownload pdfimage previewnext patent

RELATED APPLICATIONS

This application is a divisional application of copending U.S. Ser. No. 11/726,351, filed Mar. 21, 2007, which is a continuation-in-part of U.S. Ser. No. 11/491,766, filed Jul. 24, 2006, now U.S. Pat. No. 7,855,193, which claims priority to U.S. Ser. No. 60/739,466, filed Nov. 23, 2005, U.S. Ser. No. 60/753,806, filed Dec. 22, 2005, and U.S. Ser. No. 60/784,549, filed Mar. 21, 2006, and this application also claims the benefit of priority under 35 U.S.C. 119(e) to copending U.S. Provisional Application No. 60/784,549, filed on Mar. 21, 2006, the entire contents of which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity.

BACKGROUND OF THE INVENTION

Sphingosine-1-phosphate (S1P) has been demonstrated to induce many cellular effects, including those that result in platelet aggregation, cell proliferation, cell morphology, tumor cell invasion, endothelial cell chemotaxis and endothelial cell in vitro angiogenesis. S1P receptors are therefore good targets for therapeutic applications such as wound healing and tumor growth inhibition. S1P signals cells in part via a set of G protein-coupled receptors named S1P1, S1P2, S1P3, S1P4, and S1P5 (formerly called EDG-1, EDG-5, EDG-3, EDG-6, and EDG-8, respectively). These receptors share 50-55% amino acid and cluster identity with three other receptors (LPA1, LPA2, and LPA3 (formerly EDG-2, EDG-4 and EDG-7) for the structurally-related lysophosphatidic acid (LPA).

A conformational shift is induced in the G-Protein Coupled Receptor (GPCR) when the ligand binds to that receptor, causing GDP to be replaced by GTP on the α-subunit of the associated G-proteins and subsequent release of the G-proteins into the cytoplasm. The α-subunit then dissociates from the βγ-subunit, and each subunit can then associate with effector proteins, which activate second messengers leading to a cellular response. Eventually the GTP on the G-proteins is hydrolyzed to GDP, and the subunits of the G-proteins re-associate with each other and then with the receptor. Amplification plays a major role in the general GPCR pathway. The binding of one ligand to one receptor leads to the activation of many G-proteins, each capable of associating with many effector proteins, leading to an amplified cellular response.

S1P receptors make good drug targets, because individual receptors are both tissue- and response-specific. Tissue specificity of the S1P receptors is important, because development of an agonist or antagonist selective for one receptor localizes the cellular response to tissues containing that receptor, limiting unwanted side effects. Response specificity of the S1P receptors is also important because it allows for development of agonists or antagonists that initiate or suppress certain cellular responses without affecting other things. For example, the response specificity of the S1P receptors could allow for an S1P mimetic that initiates platelet aggregation without affecting cell morphology.

S1P is formed as a metabolite of sphingosine in its reaction with sphingosine kinase, and is abundantly stored in platelet aggregates where high levels of sphingosine kinase exist and sphingosine lyase is lacking. S1P is released during platelet aggregation, accumulates in serum and is also found in malignant ascites. S1P biodegradation most likely proceeds via hydrolysis by ectophosphohydrolases, specifically the sphingosine 1-phosphate phosphohydrolases.

SUMMARY

OF THE INVENTION

The present invention relates to the use of new compositions which include S1P modulators, e.g., agonists, partial agonists, inverse agonists and antagonists, and their use in treating, preventing or curing various S1P receptor-related conditions. The invention features compounds which are S1P receptor modulators; in an embodiment, such compounds include those having the formula

and pharmaceutically acceptable salts thereof, wherein R1, Z2, C, B, A, Z1, Y and X are defined herein.

DETAILED DESCRIPTION

OF THE INVENTION

In one embodiment, the present invention relates to compounds of formula I.

In formula I, A may be an aryl or heteroaryl group, optionally substituted with one, two or three substituents which may include halogen, hydroxyl, SR2, S(O)2R2, S(O)2NR2, NHS(O)2R2, COR2, CO2R2, cyano, amino, C1-5 alkylamino/arylamino/heteroarylamino, C1-6alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen-substituted C1-6 alkyl, and halogen-substituted C1-5 alkoxy. Optionally two adjacent substituents of A may, taken with Z1 and the ring A to which they are attached, form a fused ring that may optionally contain one or more hetero atoms. R2 may be selected independently from hydrogen, hydroxyl, amino, alkylamino/arylamino, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; or aryl/heteroaryl. A may desirably be a C5-6 cyclic ring (alicyclic or aromatic) optionally having one or more heteroatoms.

B and C are an at least partially aromatic bicyclic ring system, e.g., bicycloaryl, bicycloheteroaryl, dihydrobicyclic or tetrahydrobicyclic aryl and heteroaryl. The bicyclic ring system may be substituted with 1 to 5 substituents, e.g., C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen, hydroxyl, cyano, halogen-substituted C1-6alkyl and halogen-substituted C1-5 alkoxy.

Z1 and Z2 may be independently selected from O, NR3, S, S(O), S(O)2, S(O)2NR3, (CR4R5)n, C═O, C═S, C═N—R3, or a direct bond. R3 may be hydrogen, hydroxyl, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; aryl or heteroaryl. R4 and R5 may independently be hydrogen, halogen, hydroxyl, cyano, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl and halogen substituted C1-5 alkoxy; aryl or heteroaryl or together form “C═O”; n may be 0, 1, 2 or 3. In an embodiment where Z2 is a direct bond, R3 may be a C3-C6 ring optionally containing a heteroatom.

R1 may be C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-5 alkoxy, C1-5 alkylamino, aryl or heteroaryl. R1 may optionally be substituted with, e.g., hydroxyl, halogen, cyano, amino, alkylamino, aryl amino, heteroarylamino groups, and the aryl and heteroaryl groups may optionally be substituted with 1-5 substituents, e.g., hydroxyl, halogen, cyano, C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, C3-6 cycloalkyl.

X may be WC(O)OR6a, WP(O)R6bR6c, WS(O)2OH, WCONHSO3H or 1H-tetrazol-5-yl. W may be a direct bond, oxygen or C1-4 alkyl with substituents independently selected from the group consisting of: halogen, hydroxyl, cyano, amino, alkylamino, arylamino, heteroarylamino groups, C1-4 alkoxy and; R6a may be hydrogen or C1-4alkyl; R6b and R6c may be hydrogen, hydroxyl, C1-4alkyl or halogen substituted C1-4alkyl.

Y may be a residue of formula (a) where the left and right asterisks indicate the point of attachment:

wherein Q may be a direct bond, C═O, C═S, SO2, C═ONR or (CR10R11)m; m may be 0, 1, 2 or 3; R7 and R8 may be independently hydrogen, halogen, amino, C1-5 alkylamino, hydroxyl, cyano, C1-6 alkyl, C1-6 hydroxyalkyl (e.g., hydroxy-terminated alkyl), C1-5 alkylthio, C1-5 alkoxy, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; or R7 and R8 may be joined together with the atoms to which they are attached to form a 4 to 7-membered ring, optionally having a hetero atom. R9 may be hydrogen, halogen, hydroxyl, cyano, C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen-substituted C1-6 alkyl or halogen-substituted C1-5 alkoxy; R10 and R11 may individually be hydrogen, halogen, hydroxyl, cyano, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl or halogen-substituted C1-5 alkoxy.

In another embodiment, the invention includes compounds having the formula

and pharmaceutically acceptable salts thereof. In formula I, A may be a C1-6 cyclic ring (alicyclic or aromatic) that may have one or more heteroatoms. Where A is an aryl or heteroaryl group, A may be optionally substituted with one, two or three substituents which may include halogen, hydroxyl, S, S(O)2R2, S(O)2NR2, NHS(O)2R2, COR2, CO2R2, cyano, amino, C1-5 alkylamino/arylamino/heteroarylamino, C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen-substituted C1-6 alkyl, and halogen-substituted C1-5 alkoxy. Optionally two adjacent substituents may, taken with Z1 and the ring to which they are attached, form an alicyclic or heterocyclic ring, e.g. piperidinyl. R2 may be hydrogen, hydroxyl, amino, alkylamino/arylamino, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; or aryl/heteroaryl.

B and C are an at least partially aromatic bicyclic ring system, e.g., bicycloaryl, bicycloheteroaryl, dihydrobicyclic or tetrahydrobicyclic aryl and heteroaryl. The bicyclic ring system may be substituted with 1 to 5 substituents, e.g., C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen, hydroxyl, cyano, halogen-substituted C1-6alkyl and halogen-substituted C1-5 alkoxy; Z1 and Z2 may be independently selected from O, NR3, S, S(O), S(O)2, S(O)2NR3, (CR4R5)n, C═O, C═S, C═N—R3, or a direct bond. R3 may be hydrogen, hydroxyl, S(O)2, C═O, C═S, C═NH, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; aryl or heteroaryl. R4 and R5 may independently be hydrogen, halogen, hydroxyl, cyano, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; aryl or heteroaryl or together form “C═O”; n may be 0, 1, 2 or 3. R1 may be C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C1-5 alkoxy, C1-5 alkylamino, aryl or heteroaryl. R1 may optionally be substituted with, e.g., hydroxyl, halogen, cyano, amino, alkylamino, aryl amino, heteroarylamino groups, and the aryl and heteroaryl groups may optionally be substituted with 1-5 substituents, e.g., hydroxyl, halogen, cyano, C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, C3-6 cycloalkyl.

X may be WC(O)OR6a, WP(O)R6bR6c, WS(O)2OH, WCONHSO3H or 1H-tetrazol-5-yl. W may be a direct bond, oxygen or C1-4 alkyl with substituents independently selected from the group consisting of: halogen, hydroxyl, cyano, amino, alkylamino, arylamino, heteroarylamino groups, C1-4 alkoxy and COO2H; R4a may be hydrogen or C1-4alkyl; R6b and R6c may be hydrogen, hydroxyl, C1-4alkyl or halogen substituted C1-4alkyl. Y has the formula:

wherein Q may be a direct bond, C═O, C═S, SO2, C═ONR or (CR10R11)m; m may be 0, 1, 2 or 3, and R7-R8 may be hydrogen, halogen, amino, C1-5 alkylamino, hydroxyl, cyano, C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen-substituted C1-6 alkyl and halogen-substituted C1-5 alkoxy; or R7 and R8 may be joined together with the atoms to which they are attached to form a 4 to 7 member ring. R9 may be hydrogen, halogen, hydroxyl, cyano, C1-6 alkyl, C1-5 alkylthio, C1-5 alkoxy, halogen-substituted C1-6 alkyl or halogen-substituted C1-5 alkoxy; R10 and R11 may individually be hydrogen, halogen, hydroxyl, cyano, C1-6 alkyl, C1-5 alkoxy, C1-5 alkylthio, halogen-substituted C1-6 alkyl or halogen-substituted C1-5 alkoxy.

In another embodiment, the present invention relates to a compound having the formula

wherein

A is an optionally substituted aryl or heteroaryl group;

B and C are an at least partially aromatic bicyclic ring system;



Download full PDF for full patent description/claims.

Advertise on FreshPatents.com - Rates & Info


You can also Monitor Keywords and Search for tracking patents relating to this S1p receptor modulating compounds and use thereof patent application.
###
monitor keywords



Keyword Monitor How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like S1p receptor modulating compounds and use thereof or other areas of interest.
###


Previous Patent Application:
Imidazoisoindole neuropeptide s receptor antagonists
Next Patent Application:
Inhibitors of polo-like kinase
Industry Class:
Drug, bio-affecting and body treating compositions
Thank you for viewing the S1p receptor modulating compounds and use thereof patent info.
- - - Apple patents, Boeing patents, Google patents, IBM patents, Jabil patents, Coca Cola patents, Motorola patents

Results in 3.01495 seconds


Other interesting Freshpatents.com categories:
Nokia , SAP , Intel , NIKE ,

###

All patent applications have been filed with the United States Patent Office (USPTO) and are published as made available for research, educational and public information purposes. FreshPatents is not affiliated with the USPTO, assignee companies, inventors, law firms or other assignees. Patent applications, documents and images may contain trademarks of the respective companies/authors. FreshPatents is not affiliated with the authors/assignees, and is not responsible for the accuracy, validity or otherwise contents of these public document patent application filings. When possible a complete PDF is provided, however, in some cases the presented document/images is an abstract or sampling of the full patent application. FreshPatents.com Terms/Support
-g2--0.1657
     SHARE
  
           

FreshNews promo


stats Patent Info
Application #
US 20110212940 A1
Publish Date
09/01/2011
Document #
13034895
File Date
02/25/2011
USPTO Class
51421018
Other USPTO Classes
548953, 546196, 5462841, 548205, 546147, 514307, 548525, 514422, 549469, 514469, 544111, 544153, 5142335, 548252, 5142102
International Class
/
Drawings
0


Activity
Autoimmune
Bowel
General
Hemolytic
Hepatitis
Immune
Inflammatory Bowel Diseases
Lupus
Receptor


Follow us on Twitter
twitter icon@FreshPatents